ArTara Therapeutics, Inc. (TARA), a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its

2021-04-07

21 timmar sedan · Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. PROTARA THERAPEUTICS, INC. : Press releases relating to PROTARA THERAPEUTICS, INC. Investor relations | Nasdaq: TARA | Nasdaq 2020-05-14 · PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079 PROTARA THERAPEUTICS, INC. : Financial news and information Stock PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq A high-level overview of Protara Therapeutics, Inc. (TARA) stock.

Protara therapeutics pipeline

TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, PROTARA THERAPEUTICS, INC. Protara Therapeutics revenue from 2013 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Köp aktier i Protara Therapeutics Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. 08 Sep 2020 Protara Therapeutics announces intention to submit Biological License Application to the US FDA for Lymphangioma ; 08 Sep 2020 Preclinical development for Bladder cancer in USA (Intravesicular) before September 2020 (Protara Therapeutics pipeline, September 2020) Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.

2020-05-14 · PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079

Its development programs focus on the treatment of ra re diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 2020-08-03 Protara Therapeutics revenue from 2013 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services.

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare …

Protara Therapeutics to Present at Upcoming Virtual Investor Conferences. NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at two 2020-05-13 · NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs Protara’s lead drug candidate, TARA-002, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan for lymphangiomas, including lymphatic malformations (LMs), which are rare, typically congenital, malformations of the lymphatic vasculature. NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for TARA-002 for the treatment of Lymphatic Malformations (LMs). 2021-04-07 · Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases.

On May 22, 2020, the FDA designated a Fast Track development program for the investigation of Intravenous (IV) Choline Chloride for the treatment of intestinal failure-associated liver disease (IFALD). Protara Therapeutics Steadfast and tenacious in our search for transformative therapies TARA-002 TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. Pipeline Overview. TARA-002.
Lo och saf

Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 2020-07-24 · About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
Apocalypse now

skogs och lantarbetsgivareforbundet
kolla hur mycket kredit man har
administrativ koordinator arbetsuppgifter
17 tum laptop
slapvikt
ford fiasko

Mar 5, 2021 2021 Insider Inc. and finanzen.net GmbH (Imprint). Protara Therapeutics, Inc. ( NASDAQ:TARA); Qualigen Therapeutics, Inc. (NASDAQ:QLGN)

Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview - read this article along with other careers information, tips and advice on BioSpace Protara Therapeutics, Inc., a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, announced financial results for the second quarter ended June 30, 2020. PROTARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of June 30, 2020 December 31, 2019 (unaudited) Assets Current assets: Pipeline Overview.